GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bactiguard Holding AB (LTS:0QV2) » Definitions » Debt-to-EBITDA

Bactiguard Holding AB (LTS:0QV2) Debt-to-EBITDA : 19.90 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Bactiguard Holding AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bactiguard Holding AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr19.9 Mil. Bactiguard Holding AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr221.6 Mil. Bactiguard Holding AB's annualized EBITDA for the quarter that ended in Mar. 2024 was kr12.1 Mil. Bactiguard Holding AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 19.90.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Bactiguard Holding AB's Debt-to-EBITDA or its related term are showing as below:

LTS:0QV2' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -124.45   Med: 4.17   Max: 23.64
Current: -4.31

During the past 13 years, the highest Debt-to-EBITDA Ratio of Bactiguard Holding AB was 23.64. The lowest was -124.45. And the median was 4.17.

LTS:0QV2's Debt-to-EBITDA is ranked worse than
100% of 426 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs LTS:0QV2: -4.31

Bactiguard Holding AB Debt-to-EBITDA Historical Data

The historical data trend for Bactiguard Holding AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bactiguard Holding AB Debt-to-EBITDA Chart

Bactiguard Holding AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.44 23.64 -31.49 -124.45 -3.00

Bactiguard Holding AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.95 -1.67 -8.06 -3.67 19.90

Competitive Comparison of Bactiguard Holding AB's Debt-to-EBITDA

For the Medical Devices subindustry, Bactiguard Holding AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bactiguard Holding AB's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bactiguard Holding AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Bactiguard Holding AB's Debt-to-EBITDA falls into.



Bactiguard Holding AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bactiguard Holding AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(190.793 + 42.306) / -77.761
=-3.00

Bactiguard Holding AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(19.921 + 221.608) / 12.14
=19.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Bactiguard Holding AB  (LTS:0QV2) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Bactiguard Holding AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Bactiguard Holding AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Bactiguard Holding AB (LTS:0QV2) Business Description

Traded in Other Exchanges
Address
Alfred Nobels Alle 150, Box 15, Tullinge, SWE, SE 146 21
Bactiguard Holding AB is a Sweden-based medical device company. It is engaged in the development of infection prevention solutions, which reduce the risk of infections and the use of antibiotics. Its technology is based on the Bactiguard Infection Protection (BIP), a thin coating permanently bound to the surface of medical devices. Its portfolio contains urinary catheters, endotracheal tubes, central venous catheters, Hydrocyn for disinfection and wound care, as well as sutures and other wound care products. Its geographical segments are United States, Sweden, Malaysia, China, Thailand, Bangladesh, New Zeeland, and Other countries.

Bactiguard Holding AB (LTS:0QV2) Headlines

No Headlines